KALA BIO
KALA
55 hedge funds and large institutions have $249M invested in KALA BIO in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 8 closing their positions.
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
6% more funds holding
Funds holding: 52 → 55 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.35% less ownership
Funds ownership: 66.36% → 60.01% (-6.4%)
11% less capital inflows, than outflows
Capital inflows: $15.2M | Capital outflows: $17M
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
28% less call options, than puts
Call options by funds: $2.97M | Put options by funds: $4.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Caxton Corporation
Princeton,
New Jersey
|
+$2.34M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.34M |
| 3 |
BlackRock
New York
|
+$1.17M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.17M |
| 5 |
Barclays
London,
United Kingdom
|
+$586K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$3.51M |
| 2 |
Two Sigma Investments
New York
|
-$2.34M |
| 3 |
Millennium Management
New York
|
-$1.17M |
| 4 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.17M |
| 5 |
Renaissance Technologies
New York
|
-$654K |
KALA Hedge Fund Activity: Q1 2021 in Review
55 of the 5,709 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q1 2021, worth a combined $249M — down 1.4% from $252M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new KALA positions and 8 closed out — a net gain of 3 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Caxton Corporation, adding an estimated $2.34M. The largest seller was Bank of America, cutting an estimated $3.51M.
- 55 institutional investors held KALA BIO (KALA) as of Q1 2021, up from 52 in Q4 2020.
- Funds reported $249M of KALA BIO stock for Q1 2021, down 1.4% quarter-over-quarter.
- 11 funds opened new KALA BIO positions in Q1 2021 and 8 closed out, a net change of +3 holders.
- The largest KALA BIO buyer in Q1 2021 was Caxton Corporation, an estimated $2.34M added.
- The largest KALA BIO seller in Q1 2021 was Bank of America, an estimated $3.51M sold.
Based on aggregated 13F filings for Q1 2021.